Gapping Up
In reaction to strong earnings/guidance:
- DPW +37.2%, SEAC +37.1%, TLRD +14%, CMTL +7.9%, LULU +6.6%, CONN +6%, OKTA +4.9%, AVGO +4.1%, GEF +3%.
Other news:
- SAGE +46.9% (reports positive top-line results from phase 2 placebo-controlled trial of SAGE-217),
- DPW +36.9% (ended the day down 25%; after the close DPW Holdings denied rumors regarding Amazon -- has entered into no agreement and has received no order from Amazon),
- RSYS +17.2% (VIEX Capital Advisors increases active stake),
- MYO +11.2% (continued strength),
- PXS +10.2% (light volume; closed more than 20% lower on the day),
- ONCE +4.7% (Spark Therapeutics and Pfizer (PFE) announce interim data from Phase 1/2 clinical trial of investigational gene therapy for Hemophilia B was published),
- ACOR +4.7% Acorda Therapeutics resubmits its NDA for INBRIJA to the FDA,
- CLIR +3% (continued strength),
- HOME +2.2% At Home Group prices secondary offering by selling shareholders of 5 mln shares of common stock at $24.50 per share,
- OSIS +1.6% (continued weakness despite responding before the close to 'misleading' Muddy Waters Research allegations),
- PSTI +1.4% Pluristem Therapeutics to present PLX-R18 data from Phase II-equivalent study demonstrated improved survival and hematological recover,
- DG +1.3% (ahead of earnings),
- GWPH +1.1% GW Pharma prices 28.8 mln shares of common stock at $115.00 per ADS.
Analyst comments:
- LULU +8.3% (upgraded to Hold from Sell at Canaccord Genuity),
- AKS +4.8% (upgraded to Overweight from Neutral at JP Morgan),
- DVA +1.2% (upgraded to Strong Buy from Outperform at Raymond James),
- SHAK +1.1% upgraded to Equal-Weight from Underweight at Morgan Stanley).